Growth Hormone Secretagogues, Explained: Ipamorelin, CJC-1295 and the GH/IGF Axis

There is an old engineer’s instinct that runs underneath the whole growth-hormone-secretagogue story: do not import what the factory can already make. Growth hormone is a finicky thing to inject — expensive, tightly regulated, and blunt, because a steady drip overrides the body’s carefully timed nightly pulses. So a different idea took hold in the laboratory. Instead of supplying the hormone, what if you simply walked up to the pituitary and asked it, politely and repeatedly, to make more of its own? That is the entire premise of this class of peptides, and it is genuinely elegant. It is also, on close inspection, supported by an evidence base that is far thinner, and far stranger, than the supplement-aisle confidence around these molecules would lead you to believe.

What is a growth hormone secretagogue?

A secretagogue is, literally, something that triggers secretion. A growth hormone secretagogue is a compound studied to make the anterior pituitary release more of the growth hormone it already manufactures, rather than delivering the hormone from outside the body. The appeal is mechanistic: endogenous growth hormone is secreted in pulses, mostly at night, and that rhythm appears to matter biologically. A secretagogue that preserves the rhythm is, in principle, a gentler lever than a flat infusion of recombinant hormone.

Two distinct molecular families pull that lever from different sides. The first are the ghrelin mimetics, which act on the growth-hormone-secretagogue receptor (GHSR1a) — the same receptor that the hunger hormone ghrelin uses.³ The prototype here is ipamorelin, described in 1998 as “the first selective growth hormone secretagogue,” meaning it stimulated growth-hormone release without the unwanted spillover into cortisol and prolactin seen with earlier compounds.² The second family are the GHRH analogues — synthetic relatives of growth-hormone-releasing hormone, the body’s own upstream “go” signal — of which the long-acting CJC-1295 is the example most discussed today.¹³ Think of it as two keys for the same engine: ghrelin mimetics press the accelerator, GHRH analogues lengthen how long the ignition stays on.

How does ipamorelin actually work — and what is it really studied for?

Ipamorelin’s selectivity is its calling card. In the foundational pharmacology it released growth hormone with a potency comparable to earlier secretagogues but without their hormonal noise, which is why it became a reference molecule for the class.² Its pharmacokinetics were mapped early, including unusually careful work on nasal absorption as a delivery route.¹ In animal models it behaves as a clean GHSR1a agonist: it has been studied alongside anamorelin for its effects on chemotherapy-associated weight loss in ferrets,³ and even probed in fish for effects on the reproductive axis.⁴ All of that is preclinical, and worth saying plainly.

Here is the part the marketing tends to skip. The most rigorous human evidence for ipamorelin has nothing to do with anti-ageing, athletic performance, or body composition. It comes from gastrointestinal motility. Because the GHSR1a receptor is expressed in the gut and drives motility, ipamorelin was studied as a prokinetic agent for post-operative ileus — the temporary gut paralysis that follows abdominal surgery. The rodent groundwork showed it restored gastric emptying and intestinal transit in models of ileus,⁷⁸ and that line of work culminated in a prospective, randomised, controlled, proof-of-concept human trial in bowel-resection patients.⁶

That is a remarkable fact to sit with. A molecule sold around the world on the promise of recomposition and recovery has its single best controlled human dataset in a surgical-recovery indication that has nothing to do with those claims.

How does CJC-1295 differ, and what does the human data show?

CJC-1295 takes the other route. It is a GHRH analogue, engineered for a long half-life — the underlying chemistry of stabilising and extending such peptides, through modifications like PEGylation of the GRF(1-29) fragment, is its own small field.¹⁴ Crucially, when it works, it appears to work in a physiologically respectful way. In a study in healthy adults, CJC-1295 measurably activated the GH/IGF-1 axis, raising growth hormone and IGF-1 and shifting the serum protein profile accordingly.¹³ And in a key piece of human pharmacology, the compound was shown to preserve pulsatile growth-hormone secretion even under continuous stimulation — it amplified the pulses rather than flattening them into a constant tide.¹⁵ That is the design goal of the whole class, demonstrated.

But look at where CJC-1295 mostly appears in the peer-reviewed record, and the picture turns. A great deal of the published literature is not efficacy research at all — it is doping control. The compound was first characterised in an anti-doping laboratory after being identified in an unknown, unlabelled pharmaceutical preparation.¹² Subsequent work built methods to detect it in equine plasma by mass spectrometry and by immuno-PCR screening,¹⁰¹¹ the analytical signature of a substance circulating outside any approved channel. There is even a netnographic study — a study of online communities — documenting female use of CJC-1295 sourced and discussed entirely outside clinical medicine.⁹ When the literature on a compound is dominated by how to catch it rather than whether it works, that tells you something about its regulatory status.

Ghrelin mimetic versus GHRH analogue: a side-by-side

Two routes to the same physiology — pressing the pituitary’s accelerator versus extending its ignition — with very different evidence bases behind each headline claim.

What does the honest evidence actually say?

If you strip away the framing, three uncomfortable truths remain. First, none of these peptides is an approved medicine for the use it is famous for. Ipamorelin’s clinical development targeted gut motility, not ageing or muscle;⁶ CJC-1295 has no approved indication at all and surfaces chiefly in detection science.¹² The body-composition and recovery promises attached to both are extrapolations, not findings.

Second, activating the GH/IGF-1 axis is not a free lunch. IGF-1 is a growth signal, and the same biology that builds tissue sits at the centre of the deep, unresolved tension between growth and longevity — and the oncology caveats that come with chronically elevated growth signalling. We treat that trade-off in detail in our editorial on IGF-1, mTOR, muscle and longevity, and it is essential context here, because a secretagogue’s entire point is to push that axis upward. The downstream actor in that pathway is itself a research compound; see our IGF-1 LR3 primer for how the analogue chemistry compounds the unknowns.

Third, these are prohibited in sport. Growth-hormone secretagogues and GHRH analogues sit on the World Anti-Doping Agency prohibited list, which is precisely why so much of the published work consists of urine and plasma detection assays for ipamorelin and the wider GHRP family⁵ and for CJC-1295.¹¹ A compound that is principally interesting to anti-doping chemists is, by definition, not a sanctioned performance aid. For how these molecules are sometimes combined — and why combining them compounds the pharmacokinetic and safety unknowns rather than averaging them — see our analysis of peptide stacks and the evidence, and the dedicated Ipamorelin and CJC-1295 primer.

Where does that leave the responsible researcher?

The growth-hormone-secretagogue class is a beautiful idea wearing borrowed credibility. The mechanism is real and, in CJC-1295’s case, demonstrably engages the human GH/IGF-1 axis while preserving its natural rhythm.¹⁵ But the leap from “raises a hormone in a pharmacology study” to “safe, effective tool for ageing or athletic performance” is exactly the leap the data refuse to make. Ipamorelin’s strongest human evidence lives in a surgical ward;⁶ CJC-1295’s richest literature lives in the anti-doping lab.¹² Honesty about that gap is not a hedge — it is the only intellectually defensible position.

That honesty is also why identity and purity are non-negotiable. These are unapproved, multi-step synthetic peptides whose entire usefulness in a research setting depends on being exactly the molecule the label claims, at the stated purity, free of process-related contaminants. Condor Research supplies every compound in this class — ipamorelin, CJC-1295 and the rest — strictly as research-use-only reference materials, not for human or veterinary use, each accompanied by a Certificate of Analysis documenting identity and purity by HPLC and mass spectrometry. In a category this crowded with unverifiable claims, a verifiable molecule is the only foundation worth building research on.